专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20100092542A1 COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS 有权
公开(公告)号：US20100092542A1
公开(公告)日：2010-04-15
申请号：US12508367
申请日：2009-07-23
申请人： John Burnier , Thomas Gadek , Wang Shen , Johan D. Oslob , Kenneth Barr
发明人： John Burnier , Thomas Gadek , Wang Shen , Johan D. Oslob , Kenneth Barr
IPC分类号： A61K9/00 , A61K9/127 , A61K9/12 , A61K31/4725 , C07D401/14 , A61P27/02
CPC分类号： A61K31/4725 , A61B3/101 , A61B3/145 , A61K9/0014 , A61K9/0019 , A61K9/0043 , A61K9/0048 , A61K9/0051 , A61K9/0053 , A61K31/197 , A61K31/198 , A61K31/275 , A61K31/341 , A61K31/352 , A61K31/381 , A61K31/40 , A61K31/404 , A61K31/405 , A61K31/4162 , A61K31/4184 , A61K31/4192 , A61K31/44 , A61K31/4709 , A61K31/472 , A61K31/4745 , A61K31/495 , A61K31/496 , A61K31/517 , A61K31/5377 , A61K31/54 , A61K31/541 , A61K33/00 , A61K33/06 , A61K38/07 , A61K38/08 , A61K38/12 , A61K38/1703 , A61K45/06 , C07C279/28 , C07C317/50 , C07D207/06 , C07D217/00 , C07D217/02 , C07D217/06 , C07D217/20 , C07D217/26 , C07D307/52 , C07D333/38 , C07D401/06 , C07D405/06 , C07D405/14 , C07D409/14 , C07D413/14 , C07D471/04 , G01N33/5011 , G01N33/5032 , G01N33/5047 , G01N33/566 , G01N33/6872 , G01N2333/705 , G01N2333/70525 , G01N2333/70546 , G01N2500/02 , G01N2500/04 , G01N2500/10 , G01N2500/20 , G01N2800/16 , Y10S514/912 , Y10S514/914
摘要： The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.

12. 发明申请

US20090137561A1 Substituted biphenyl GPR40 modulators 有权
公开(公告)号：US20090137561A1
公开(公告)日：2009-05-28
申请号：US12287036
申请日：2008-10-03
申请人： Sean P. Brown , Qiong Cao , Paul John Dransfield , Xiaohui Du , Jonathan Houze , Xian Yun Jiao , Yong-Jae Kim , Todd J. Kohn , SuJen Lai , An-Rong Li , Daniel Lin , Jian Luo , Julio C. Medina , Jeffrey D. Reagan , Vatee Pattaropong , Margrit Schwarz , Wang Shen , Yongli Su , Gayathri Swaminath , Marc Vimolratana , Xiang Wang , Yumei Xiong , Li Yang , Ming Yu , Jie Zhang , Liusheng Zhu
发明人： Sean P. Brown , Qiong Cao , Paul John Dransfield , Xiaohui Du , Jonathan Houze , Xian Yun Jiao , Yong-Jae Kim , Todd J. Kohn , SuJen Lai , An-Rong Li , Daniel Lin , Jian Luo , Julio C. Medina , Jeffrey D. Reagan , Vatee Pattaropong , Margrit Schwarz , Wang Shen , Yongli Su , Gayathri Swaminath , Marc Vimolratana , Xiang Wang , Yumei Xiong , Li Yang , Ming Yu , Jie Zhang , Liusheng Zhu
IPC分类号： C07C59/48 , A61K31/192 , A61K31/235 , C07C69/76 , C07D309/00 , A61K31/351 , C07D211/20 , A61K31/445 , A61K31/44 , A61K31/55 , C07D223/04 , A61P7/00
CPC分类号： C07C323/62 , C07C59/68 , C07C59/72 , C07C217/54 , C07C217/62 , C07C317/22 , C07C323/19 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/10 , C07C2601/14 , C07C2601/16 , C07C2601/18 , C07C2602/42 , C07C2603/74 , C07D213/64 , C07D309/12
摘要： The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

13. 发明授权

US07504512B2 N-acylsulfonamide apoptosis promoters 有权
标题翻译： N-酰基磺酰胺凋亡启动子
公开(公告)号：US07504512B2
公开(公告)日：2009-03-17
申请号：US10820097
申请日：2004-04-07
申请人： David J. Augeri , Steven A. Baumeister , Milan Bruncko , Daniel A. Dickman , Hong Ding , Jurgen Dinges , Stephen W. Fesik , Philip J. Hajduk , Aaron R. Kunzer , William McClellan , David G. Nettesheim , Thorsten Oost , Andrew M. Petros , Saul H. Rosenberg , Wang Shen , Sheela A. Thomas , Xilu Wang , Michael D. Wendt
发明人： David J. Augeri , Steven A. Baumeister , Milan Bruncko , Daniel A. Dickman , Hong Ding , Jurgen Dinges , Stephen W. Fesik , Philip J. Hajduk , Aaron R. Kunzer , William McClellan , David G. Nettesheim , Thorsten Oost , Andrew M. Petros , Saul H. Rosenberg , Wang Shen , Sheela A. Thomas , Xilu Wang , Michael D. Wendt
IPC分类号： C07C211/00 , A61K31/445
CPC分类号： C07D207/27 , A61K31/18 , A61K31/4015 , A61K31/44 , A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61K31/541 , C07C311/51 , C07C323/30 , C07C323/37 , C07C2601/08 , C07C2601/14 , C07C2601/16 , C07C2601/18 , C07C2602/42 , C07C2603/74 , C07D203/26 , C07D207/06 , C07D209/08 , C07D209/52 , C07D209/54 , C07D211/22 , C07D211/74 , C07D213/54 , C07D213/61 , C07D213/64 , C07D213/70 , C07D213/78 , C07D215/12 , C07D221/20 , C07D231/12 , C07D235/08 , C07D235/26 , C07D239/26 , C07D249/04 , C07D263/32 , C07D263/56 , C07D263/58 , C07D277/56 , C07D277/64 , C07D295/205 , C07D295/26 , C07D317/60 , C07D333/28 , C07D333/56 , C07D333/70 , C07D417/12 , C07D451/02
摘要： N-Benzoyl arylsulfonamides having the formula are BCL-X1 inhibitors and are useful for promoting apoptosis. Also disclosed are BCL-X1 inhibiting compositions and methods of promoting apoptosis in a mammal.
摘要翻译：具有下式的N-苯甲酰基芳基磺酰胺是BCL-X1抑制剂，可用于促进凋亡。还公开了BCL-X1抑制组合物和促进哺乳动物细胞凋亡的方法。

14. 发明授权

US07497712B2 Method for fabricating microconnector and shape of terminals thereof 有权
标题翻译：微连接器的制造方法及其端子的形状
公开(公告)号：US07497712B2
公开(公告)日：2009-03-03
申请号：US11806917
申请日：2007-06-05
申请人： Ben-Hwa Jang , Shin-Way Lin , Wei-Leun Fang , Wang-Shen Su
发明人： Ben-Hwa Jang , Shin-Way Lin , Wei-Leun Fang , Wang-Shen Su
IPC分类号： H01R13/193
CPC分类号： H01R13/504 , H01R13/639 , H01R13/6581 , H01R24/62 , H01R2107/00
摘要： A method for fabricating a microconnector and the shape of terminals of the microconnector is proposed, which combines a cover with a base as a female connector, inserts an inserting member as a male connector between the cover and the base, and the ends of the terminals at the base electrically connecting the inserting member undergoing plasma treatment for controlling the shape thereof. The terminals of the microconnector can be actuated with by a low voltage. By such arrangement, the inserting member can be firmly engaged and the intervals between terminals and the overall size of the microconnector can be reduced while providing low insertion force and electrostatic actuating force.
摘要翻译：提出了一种用于制造微型连接器的方法和微型连接器的端子的形状，其将作为母连接器的基座的盖结合，将作为阳连接器的插入构件插入到盖和基座之间，并且端子的端部在基座上电连接经受等离子体处理的插入件以控制其形状。微型连接器的端子可以通过低电压启动。通过这种布置，插入构件可以牢固地接合，并且可以在提供低插入力和静电致动力的同时减小端子之间的间隔和微型连接器的整体尺寸。

15. 发明申请

US20080312270A1 COMPOUNDS AND METHODS USEFUL FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION 有权
标题翻译：用于治疗哮喘和过敏性炎症的化合物和方法
公开(公告)号：US20080312270A1
公开(公告)日：2008-12-18
申请号：US12113121
申请日：2008-04-30
申请人： Matthew Brown , Michael G. Johnson , An-Rong Li , Jiwen Liu , Sarah E. Lively , Julio C. Medina , Wang Shen , Xuemei Wang , Yingcai Wang
发明人： Matthew Brown , Michael G. Johnson , An-Rong Li , Jiwen Liu , Sarah E. Lively , Julio C. Medina , Wang Shen , Xuemei Wang , Yingcai Wang
IPC分类号： A61K31/437 , C07D209/04 , A61K31/404 , C07D277/62 , A61K31/428 , C07D235/04 , A61K31/4184 , C07K14/00 , A61P17/00 , A61P35/00 , A61P1/00 , A61P19/02 , A61P3/00 , A61P11/00 , C12N5/00 , C07D231/54 , A61K31/416 , A61K31/47 , C07D215/00 , C07D471/02
CPC分类号： C07D209/08 , C07D209/10 , C07D209/34 , C07D209/42 , C07D209/48 , C07D213/68 , C07D213/76 , C07D215/38 , C07D231/56 , C07D235/08 , C07D235/22 , C07D277/82 , C07D405/12 , C07D471/04
摘要： Compounds, compositions and methods that are useful in the treatment of inflammatory and immune-related diseases and conditions are provided herein. In particular, the invention provides compounds which modulate the function and/or expression of proteins involved in atopic diseases, inflammatory conditions and cancer. The subject compounds are carboxylic acid derivatives.
摘要翻译：本文提供了可用于治疗炎症和免疫相关疾病和病症的化合物，组合物和方法。特别地，本发明提供调节参与特应性疾病，炎性病症和癌症的蛋白质的功能和/或表达的化合物。主题化合物是羧酸衍生物。

16. 发明申请

US20050267098A1 Modulators of cellular adhesion 有权
标题翻译：细胞粘附的调节剂
公开(公告)号：US20050267098A1
公开(公告)日：2005-12-01
申请号：US10982463
申请日：2004-11-05
申请人： Wang Shen , Kenneth Barr , Johan Oslob , Min Zhong
发明人： Wang Shen , Kenneth Barr , Johan Oslob , Min Zhong
IPC分类号： A61K31/47 , A61K31/502 , A61K31/517 , A61K31/55 , C07D217/06 , C07D231/56 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/06 , C07D405/12 , C07D407/14 , C07D409/12 , C07D409/14
CPC分类号： A61K31/4725 , A61K31/472 , A61K31/506 , A61K31/517 , A61K45/06 , C04B35/632 , C07D217/06 , C07D217/16 , C07D217/26 , C07D231/56 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/06 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14
摘要： The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).
摘要翻译：本发明提供具有式（I）的化合物及其药学上可接受的衍生物，其中R 1 -R 4，n，p，A，B，D，E， L和AR 1如本文所述的一般类型和亚类所述，并且另外提供其药物组合物及其用于治疗由CD11 / CD18家族介导的细胞粘附的疾病的方法分子（如LFA-1）。

17. 发明授权

US06204293B1 Inhibitors of protein isoprenyl transferases 失效
标题翻译：蛋白质异戊二烯转移酶抑制剂
公开(公告)号：US06204293B1
公开(公告)日：2001-03-20
申请号：US09073807
申请日：1998-05-07
申请人： Said M. Sebti , Andrew D. Hamilton , David J. Augeri , Kenneth J. Barr , Stephen A. Fakhoury , David A. Janowick , Douglas M. Kalvin , Stephen J. O'Connor , Saul H. Rosenberg , Wang Shen , Rolf E. Swenson , Bryan K. Sorensen , Gerard M. Sullivan , Andrew S. Tasker , James T. Wasicak , Lissa T. J. Nelson , Kenneth J. Henry , Le Wang , Gang Liu , Indrani W. Gunawardana
发明人： Said M. Sebti , Andrew D. Hamilton , David J. Augeri , Kenneth J. Barr , Stephen A. Fakhoury , David A. Janowick , Douglas M. Kalvin , Stephen J. O'Connor , Saul H. Rosenberg , Wang Shen , Rolf E. Swenson , Bryan K. Sorensen , Gerard M. Sullivan , Andrew S. Tasker , James T. Wasicak , Lissa T. J. Nelson , Kenneth J. Henry , Le Wang , Gang Liu , Indrani W. Gunawardana
IPC分类号： C07C26302
CPC分类号： C07C237/36 , C07B2200/07 , C07C239/20 , C07C271/22 , C07C317/50 , C07C323/59 , C07C323/60 , C07C327/42 , C07C2601/02 , C07C2601/04 , C07C2601/14 , C07C2602/08 , C07C2603/18 , C07C2603/24 , C07C2603/74 , C07D205/04 , C07D207/08 , C07D207/09 , C07D207/10 , C07D207/12 , C07D207/26 , C07D207/267 , C07D209/48 , C07D211/14 , C07D211/42 , C07D211/52 , C07D211/58 , C07D213/30 , C07D213/32 , C07D213/34 , C07D213/36 , C07D213/38 , C07D213/56 , C07D213/64 , C07D213/65 , C07D213/68 , C07D213/70 , C07D213/71 , C07D213/74 , C07D213/75 , C07D213/76 , C07D213/82 , C07D213/89 , C07D231/12 , C07D233/56 , C07D233/64 , C07D233/90 , C07D235/06 , C07D237/14 , C07D239/26 , C07D239/42 , C07D241/04 , C07D241/12 , C07D241/18 , C07D249/08 , C07D253/06 , C07D257/04 , C07D261/02 , C07D263/22 , C07D263/32 , C07D265/30 , C07D277/30 , C07D277/36 , C07D277/48 , C07D277/50 , C07D277/587 , C07D279/12 , C07D295/084 , C07D295/13 , C07D295/155 , C07D295/185 , C07D307/54 , C07D307/81 , C07D317/30 , C07D317/60 , C07D333/18 , C07D333/20 , C07D333/24 , C07D401/12 , C07D405/04 , C07D405/12 , C07D409/12 , C07D417/12 , C07D487/08 , C07F9/5333
摘要： Compounds having the formula or a pharmaceutically acceptable salt thereof wherein R1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L2—, and (i) heterocyclic-L2—; R2 is selected from (b) —C(O)NH—CH(R14)—C(O)OR15, (d) —C(O)NH—CH(R14)—C(O)NHSO2R16, (e) —C(O)NH—CH(R14)-tetrazolyl, (f) —C(O)NH-heterocyclic, and (g) —C(O)NH—CH(R14)—C(O)NR17R18; R3 is heterocyclic, aryl, substituted or unsubstituted cycloalkyl; R4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L1 is absent or is selected from (a) —L4—N(R5)—L5—, (b) —L4—O—L5—, (c) —L4—S(O)n—L5— (d) —L4—L6—C(W)—N(R5)—L5—, (e) —L4—L6—S(O)m—N(R5)—L5 —, (f) —L4—N(R5)—C(W)—L7—L5 —, (g) —L4—N(R5)—S(O)p—L7—L5—, (h) optionally substituted alkylene, (i) optionally substituted alkenylene, and (j) optionally substituted alkynylene are inhibitors of protein isoprenyl transferases. Also disclosed are protein isoprenyl transferase inhibiting compositions and a method of inhibiting protein isoprenyl transferases.
摘要翻译：具有式的化合物或其药学上可接受的盐，其中R 1是（a）氢，（b）低级烷基，（c）烯基，（d）烷氧基，（e）硫代烷氧基，（f）卤素，（g）卤代烷基，（h）芳基-L2-和（i）杂环-L2-; R2选自（b）-C（O）NH-CH（R14）-C（O）OR15，（d）-C（O）NH-CH（R14）-C（O）NHSO2R16，（e） C（O）NH-CH（R 14） - 四唑基，（f）-C（O）NH-杂环基和（g）-C（O）NH-CH（R 14）-C（O）NR 17 R 18; R3是杂环，芳基，取代或未取代的环烷基; R4是氢，低级烷基，卤代烷基，卤素，芳基，芳基烷基，杂环或（杂环）烷基; （a）-L4-N（R5）-L5-，（b）-L4-O-L5-，（c）-L4-S（O）n-L5-（d） - L4-L6-C（W）-N（R5）-L5-，（e）-L4-L6-S（O）mN（R5）-L5 - ，（f）-L4-N（R5）-C W）-L7-L5 - ，（g）-L4-N（R5）-S（O）p-L7-L5-，（h）任选取代的亚烷基，（i）任选取代的亚烯基，和（j）亚炔基是蛋白质异戊二烯转移酶的抑制剂。还公开了蛋白质异戊二烯转移酶抑制组合物和抑制蛋白质异戊二烯转移酶的方法。

18. 发明授权

US5541327A Preparation of camptothecin analogs 失效
标题翻译：喜树碱类似物的制备
公开(公告)号：US5541327A
公开(公告)日：1996-07-30
申请号：US340034
申请日：1994-11-14
申请人： Samuel J. Danishefsky , William G. Bornmann , Wang Shen , Craig A. Coburn
发明人： Samuel J. Danishefsky , William G. Bornmann , Wang Shen , Craig A. Coburn
IPC分类号： C07D491/14 , C07D491/147 , C07D491/22 , C07H17/00
CPC分类号： C07D491/14 , C07H17/00
摘要： Substituted analogues of camptothecin possessing cytotoxic activity towards cancer cells, of the general structure: ##STR1## wherein E is H, CO.sub.2 R, CONH.sub.2, CONHR, CONR.sub.2, acyl, or CN; X is H, OH, or OR; R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are independently the same or different and are H, or a linear or branched chain alkyl, alkylaryl, or hydroxyalkyl group, or an aryl group; R.sup.5, R.sup.6, R.sup.7, R.sup.8, and R.sup.9 are independently the same or different and are H, or a linear or branched chain alkyl, alkylaryl, alkoxy, hydroxyalkyl, or aminoalkoxy group, or an aryl or aryloxy group, or a C-glycal, or CO.sub.2 R, nitro, cyano, Cl, F, Br, I, SR.sup.10, NR.sup.11 R.sup.12, OR.sup.13 ; R is H, or a linear or branched chain alkyl, alkylaryl, or hydroxyalkyl group, or an aryl group; R.sup.10, R.sup.11 and R.sup.12 are independently the same or different and are H, or a linear or branched chain alkyl, alkylaryl, hydroxyalkyl, or acyl group, or an aryl group; R.sup.13 is glycosyl; n is 0 or 1; with the proviso that when R.sup.1 is ethyl, and n is 0, E, R.sup.2, R.sup.3, and R.sup.4 are not all H. Intermediate compounds leading to the camptothecin analogues comprise substituted tricyclic compounds which consist of rings C, D, and E fused together. Methods for preparing the analogues involve condensation of such intermediates with variably substituted protected .alpha.-aminobenzaldehydes.
摘要翻译：具有一般结构的具有对癌细胞的细胞毒性活性的喜树碱的取代类似物：其中E是H，CO 2 R，CONH 2，CONHR，CONR 2，酰基或CN; X是H，OH或OR; R 1，R 2，R 3和R 4独立地相同或不同，为H，或直链或支链烷基，烷基芳基或羟烷基或芳基; R 5，R 6，R 7，R 8和R 9独立地相同或不同，为H，或直链或支链烷基，烷基芳基，烷氧基，羟基烷基或氨基烷氧基，或芳基或芳氧基或C- ，或CO 2 R，硝基，氰基，Cl，F，Br，I，SR10，NR 11 R 12，OR 13; R为H或直链或支链烷基，烷基芳基或羟烷基或芳基; R 10，R 11和R 12独立地相同或不同，为H，或直链或支链烷基，烷基芳基，羟基烷基或酰基或芳基; R13是糖基; n为0或1; 条件是当R 1为乙基且n为0时，E，R 2，R 3和R 4不全为H.导致喜树碱类似物的中间体化合物包含由稠合在一起的环C，D和E组成的取代的三环化合物。制备类似物的方法涉及这种中间体与可变取代的被保护的α-氨基苯甲醛的缩合。

19. 发明申请

US20140221406A1 QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE 有权
标题翻译：喹唑啉-7-醚化合物及其使用方法
公开(公告)号：US20140221406A1
公开(公告)日：2014-08-07
申请号：US14118200
申请日：2012-05-17
申请人： Wang Shen , Wei Xiao , Jack Maung , Aimin Zhang , Xiaoling Zheng , Zhenzhong Wang , Qingming Guo , Yingguang Li
发明人： Wang Shen , Wei Xiao , Jack Maung , Aimin Zhang , Xiaoling Zheng , Zhenzhong Wang , Qingming Guo , Yingguang Li
IPC分类号： C07D405/12 , C07D493/04
CPC分类号： C07D405/12 , C07D493/04
摘要： The invention provides quinazoline-7-ether derivatives, particularly 4-anilinyl-6-butenamido-quinazoline-7-ether derivatives that are inhibitors of the receptor protein tyrosine kinases (RTK). The compounds are useful in the treatment of diseases and disorders where RTK activity is implicated such as a hyperproliferative diseases (e.g., cancer). Also provided are methods of preparation of the quinazoline derivatives and methods of use as therapeutic agents alone or in a drug combination.
摘要翻译：本发明提供了喹唑啉-7-醚衍生物，特别是作为受体蛋白酪氨酸激酶（RTK）抑制剂的4-苯乙烯基-6-丁烯酰氨基 - 喹唑啉-7-醚衍生物。所述化合物可用于治疗涉及RTK活性的疾病和病症，例如过度增殖性疾病（例如癌症）。还提供了制备喹唑啉衍生物的方法和单独使用或作为药物组合用作治疗剂的方法。

20. 发明授权

US08450522B2 Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders 有权
标题翻译：用于治疗代谢紊乱的构象受限的羧酸衍生物
公开(公告)号：US08450522B2
公开(公告)日：2013-05-28
申请号：US12863578
申请日：2009-03-04
申请人： Sean P. Brown , Paul J. Dransfield , Jonathan Houze , Todd J. Kohn , Jiwen Liu , Julio Medina , Vatee Pattaropong , Wang Shen , Marc Vimolratana , Yingcai Wang , Ming Yu , Liusheng Zhu
发明人： Sean P. Brown , Paul J. Dransfield , Jonathan Houze , Todd J. Kohn , Jiwen Liu , Julio Medina , Vatee Pattaropong , Wang Shen , Marc Vimolratana , Yingcai Wang , Ming Yu , Liusheng Zhu
IPC分类号： C07C63/00 , A61K31/185
CPC分类号： C07C59/72
摘要： The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I or the general formula III: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.
摘要翻译：本发明提供了可用于例如治疗受试者的代谢紊乱的化合物。这些化合物具有通式I或通式III：其中本文提供变量的定义。本发明还提供了组合物，其包括化合物在制备药物和用于治疗代谢性疾病例如II型糖尿病中的使用方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式